EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol

Paulo R Shiroma, Paul Thuras, Melissa A Polusny, Shannon Kehle-Forbes, Seth Disner, Jose V Pardo, Casey Gilmore, Brian Tolly, Emily Voller, Eliza McManus, Christie King, Alexandra Lipinski und 3 weitere

Contemporary Clinical Trials · 2024-08 · 143 · 107569

DOI: 10.1016/j.cct.2024.107569 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2024-08. Verfasst von Paulo R Shiroma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Service Line, Minneapolis VA Health Care System, Minneapolis, MN, United States of America; Department of Psychiatry and Behavioral Sci…. Hauptthemen laut MEDLINE: Implosive Therapy, Ketamine, Stress Disorders, Post-Traumatic, Veterans. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, RRD VA, VA ORD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure (PE) over pharmacologic interventions for the primary treatment of PTSD. Unfortunately, clinical trials of trauma-based therapies in the military and veteran population showed that 30% to 50% of patients did not demonstrate clinically meaningful symptom change. Ketamine, an FDA-approved anesthetic with potent non-competitive glutamatergic N-methyl-d-aspartate antagonistic properties, has demonstrated to enhance the recall of extinction learning and decrease fear renewal without interference of extinction training in preclinical studies. METHODS: We plan to conduct a single site RCT comparing three ketamine treatment vs. active placebo (midazolam) adjunct to PE therapy among Veterans with PTSD. Pharmacological phase will start simultaneously with PE session 1. Infusions will be administered 24 h. prior to PE session for the first 3 weeks. After PE is completed (session 10), patients will be assessed during a 3-month follow-up period at various time points. We estimate that out of 100 veterans, 80 will reach time point for primary outcome measure and will be considered for primary analysis. Secondary outcomes include severity of depression and anxiety scores, safety and tolerability of ketamine-enhanced PE therapy, cognitive performance during treatment and early improvement during PE related to the rate of dropouts during PE therapy. DISCUSSION: Results of the proposed RCT could provide scientific foundation to distinguish the essential components of this approach, enhance the methodology, elucidate the mechanisms involved, and identify sub-PTSD populations that most likely benefit from this intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Implosive TherapyKetamineStress Disorders, Post-TraumaticVeteransAdultHumansMaleCombined Modality TherapyDouble-Blind MethodMidazolamRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

KetaminePTSDProlonged exposureVeterans

Substanzen

KetamineMidazolam

Autor:innen und Institutionen

  • Mental Health Service Line, Minneapolis VA Health Care System, Minneapolis, MN, United States of America; Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN, United…
  • Department of Anesthesiology, Minneapolis VA Health Care System, Minneapolis, MN, United States of America.
  • Mental Health Service Line, Minneapolis VA Health Care System, Minneapolis, MN, United States of America.
  • Mental Health Service Line, VA Maryland Health Care System, Baltimore, MD, United States of America.
  • Mental Health Service Line, Minneapolis VA Health Care System, Minneapolis, MN, United States of America; Graduate School of Professional Psychology, Morrison Family College of Health, University of St. Thomas, Saint Pa…

Förderung

  • CSRD VA
  • RRD VA
  • VA ORD

Zitieren

APA

Shiroma, P. R., Thuras, P., Polusny, M. A., Kehle-Forbes, S., Disner, S., Pardo, J. V., Gilmore, C., Tolly, B., Voller, E., McManus, E., King, C., Lipinski, A., Eng, E., Hawkinson, F., & Wang, G. (2024). Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol. Contemporary Clinical Trials, 143, 107569. https://doi.org/10.1016/j.cct.2024.107569

Vancouver

Shiroma PR, Thuras P, Polusny MA, Kehle-Forbes S, Disner S, Pardo JV, et al. Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol. Contemporary Clinical Trials. 2024;143:107569. doi:10.1016/j.cct.2024.107569

BibTeX
@article{Shiroma2024,
  author = {Shiroma, Paulo R and Thuras, Paul and Polusny, Melissa A and Kehle-Forbes, Shannon and Disner, Seth and Pardo, Jose V and Gilmore, Casey and Tolly, Brian and Voller, Emily and McManus, Eliza and King, Christie and Lipinski, Alexandra and Eng, Emily and Hawkinson, Francine and Wang, Gloria},
  title = {Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol},
  journal = {Contemporary Clinical Trials},
  year = {2024},
  volume = {143},
  pages = {107569},
  doi = {10.1016/j.cct.2024.107569}
}
Kostenlos starten →